SGHT has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
SGHT has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Net margin is calculated as Net Income divided by its Revenue. Sight Sciences's Net Income for the three months ended in Dec. 2024 was $-11.85 Mil. Sight Sciences's Revenue for the three months ended in Dec. 2024 was $19.07 Mil. Therefore, Sight Sciences's net margin for the quarter that ended in Dec. 2024 was -62.11%.
The historical rank and industry rank for Sight Sciences's Net Margin % or its related term are showing as below:
The historical data trend for Sight Sciences's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sight Sciences Annual Data | ||||||||||||||||
Trend | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | Dec24 | |||||||||
Net Margin % | Get a 7-Day Free Trial | -125.52 | -128.61 | -120.90 | -68.53 | -64.49 |
Sight Sciences Quarterly Data | ||||||||||||||||||||
Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | Dec24 | |
Net Margin % | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
-57.02 | -84.43 | -57.69 | -54.90 | -62.11 |
For the Medical Devices subindustry, Sight Sciences's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Devices & Instruments industry and Healthcare sector, Sight Sciences's Net Margin % distribution charts can be found below:
* The bar in red indicates where Sight Sciences's Net Margin % falls into.
Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.
Sight Sciences's Net Margin for the fiscal year that ended in Dec. 2024 is calculated as
Net Margin | = | Net Income (A: Dec. 2024 ) | / | Revenue (A: Dec. 2024 ) |
= | -51.507 | / | 79.866 | |
= | -64.49 % |
Sight Sciences's Net Margin for the quarter that ended in Dec. 2024 is calculated as
Net Margin | = | Net Income (Q: Dec. 2024 ) | / | Revenue (Q: Dec. 2024 ) |
= | -11.846 | / | 19.074 | |
= | -62.11 % |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sight Sciences (NAS:SGHT) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Thank you for viewing the detailed overview of Sight Sciences's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.
Jeremy B. Hayden | officer: Chief Legal Officer | 2 MUSICK, 2 MUSICK, IRVINE CA 92618 |
David Badawi | director, officer: Chief Technology Officer | C/O SIGHT SCIENCES, INC., 4040 CAMPBELL AVENUE, SUITE 100, MENLO PARK CA 94025 |
Paul Badawi | director, 10 percent owner, officer: President and CEO | C/O SIGHT SCIENCES, INC., 4040 CAMPBELL AVENUE, SUITE 100, MENLO PARK CA 94025 |
Alison Bauerlein | officer: See remarks | 326 BOLLAY DRIVE, GOLETA CA 93117 |
Staffan Encrantz | director | C/O SIGHT SCIENCES, INC., 4040 CAMPBELL AVENUE, SUITE 100, MENLO PARK CA 94025 |
Matthew Link | officer: Chief Commercial Officer | 7475 LUSK BLVD, SAN DIEGO CA 92121 |
Sam Boong Park | officer: Chief Operating Officer | C/O SIGHT SCIENCES, INC., 4040 CAMPBELL AVENUE, SUITE 100, MENLO PARK CA 94025 |
D1 Capital Partners L.p. | 10 percent owner | 9 WEST 57TH STREET, 36TH FLOOR, NEW YORK NY 10019 |
Catherine Mazzacco | director | C/O KRYSTAL BIOTECH, INC., 2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 15203 |
James Rodberg | officer: See Remarks | C/O SIGHT SCIENCES, INC., 4040 CAMPBELL AVE., SUITE 100, MENLO PARK CA 94025 |
Tamara Fountain | director | C/O RXSIGHT, INC., 100 COLUMBIA, ALISO VIEJO CA 92656 |
Brenda Jane Larsen-becker | director | C/O SIGHT SCIENCES, INC., 3000 SAND HILL ROAD, BUILDING 3, STE 105, MENLO PARK CA 94025 |
Jesse Selnick | officer: Chief Financial Officer | C/O SIGHT SCIENCES, INC., 4040 CAMPBELL AVENUE, SUITE 100, MENLO PARK CA 94025 |
Daniel S. Sundheim | 10 percent owner | C/O D1 CAPITAL PARTNERS L.P., 9 WEST 57TH STREET, 36TH FLOOR, NEW YORK NY 10019 |
Hh Sight Llc | 10 percent owner | 2200 ROSS AVENUE, SUITE 4600 W, DALLAS TX 75201 |
From GuruFocus
By GuruFocus Research • 08-01-2024
By Marketwired • 02-13-2025
By Marketwired • 10-14-2024
By GuruFocus News • 11-08-2024
By Marketwired • 11-07-2024
By Marketwired • 08-20-2024
By GuruFocus Research • 08-02-2024
By Marketwired • 05-07-2024
By GuruFocus News • 11-08-2024
By Marketwired • 01-14-2025
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.